Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 92

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Cholangiocarcinoma

Recruiting

Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Transthera Sciences (Nanjing) Inc.

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasm malignant

Recruiting

Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bioinvent International AB

Fallopian tube cancer+5

Recruiting

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Cholangiocarcinoma

Recruiting

Study on the Impact of [18F]-AlF-FAPI-74, Glucagon, and Hyoscine Butylbromide in Patients with Resectable Biliary Tract Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glucagon
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cervix carcinoma

Recruiting

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Neoplasm

Recruiting

Study on the Safety and Efficacy of Tretinoin with Radiation Therapy for Patients with Oligometastatic Solid Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tretinoin
  • Sponsor:Institut Gustave Roussy

Lymphoma

Recruiting

Study on the Effectiveness of Rituximab and Drug Combination for Patients with High-Risk Aggressive B-Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Karolinska University Hospital

Plasma cell myeloma

Recruiting

Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Non-small cell lung cancer metastatic

Recruiting

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Vulval cancer

Recruiting

Study on the Safety of Using Chemoradiation with Cisplatin and Carboplatin for Early-Stage Vulvar Cancer Patients with Macrometastasis in Sentinel Lymph Node

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitair Medisch Centrum Groningen

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.